NCT05005455View on ClinicalTrials.gov

Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

January 28, 2022

Study Completion Date

January 28, 2022

Conditions
Healthy Male Subjects
Interventions
DRUG

bevacizumab with new manufacturing process.

3mg/kg,I.V.,single dose

DRUG

bevacizumab with old manufacturing process.

3mg/kg,I.V.,single dose

Trial Locations (1)

215006

The first affiliated hospital of Soochow university, Suzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT05005455 - Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects | Biotech Hunter | Biotech Hunter